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APRILAbstract Aim of the work: To assess serum levels of B lymphocyte stimulator (BLyS) and a pro-
liferation-inducing ligand (APRIL) to determine their correlations with disease activity in pediatric
systemic lupus erythematosus (pSLE) and juvenile idiopathic arthritis (JIA) patients.
Patients and methods: Twenty-nine pSLE patients and 33 JIA patients were recruited. SLE dis-
ease activity was assessed using the systemic lupus erythematosus disease activity index (SLEDAI),
while the juvenile arthritis 27 joint disease activity score (JADAS-27) was calculated for JIA
patients. Serum samples were assayed for BLyS and APRIL by the enzyme linked immunosorbent
assay (ELISA).
Results: Serum BLyS and APRIL were elevated in both pSLE and JIA patients compared to
controls. Serum BLyS levels correlated with both SLE and JIA disease activity (p= 0.042,
p= 0.019, respectively) whereas serum APRIL levels correlated positively with JADAS-27 and
inversely with SLEDAI (p= 0.001, p= 0.02, respectively). Elevated serum BLyS and APRIL were
signiﬁcantly associated with a lower incidence of nephritis (p= 0.043, p= 0.016, respectively),
while elevated serum APRIL signiﬁcantly associated with negative anti-dsDNA in pSLE patients
(p= 0.017). In JIA patients, both serum BLyS and APRIL were signiﬁcantly associated with the
94 G.G. Elolemy et al.presence of ANA (p= 0.008, p< 0.001, respectively), while high serum APRIL associated with the
presence of RF (p= 0.035). APRIL and BLYS levels correlated with each other positively in JIA
but inversely in pSLE patients.
Conclusion: Serum BLyS showed elevated levels that correlated signiﬁcantly with pSLE and JIA
disease activity, accordingly anti-BLyS therapy might be of great beneﬁt to offset disease ﬂare. The
inverse correlations observed between APRIL with both BLyS and disease activity in pSLE patients
raises the possibility of being a down regulator of the disease process.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Emerging data from clinical trials are providing a critical in-
sight regarding the role of B cells and autoantibodies in vari-
ous autoimmune conditions. Deregulated B-cell function has
been implicated in several autoimmune diseases, including sys-
temic lupus erythematosus, rheumatoid arthritis, and multiple
sclerosis. B cells contribute to pathological immune responses
through the secretion of cytokines, costimulation of T cells,
antigen presentation, and the production of autoantibodies [1].
Given the crucial role of B cells in the pathogenesis of SLE
and RA, it stands to reason that factors which promote B cell
survival and/or function are also crucial [2]. B-lymphocyte
stimulator (BLyS)––also called B cell-activating factor belong-
ing to the tumor necrosis factor family (BAFF)––and a prolif-
eration-inducing ligand (APRIL) are members of the tumor
necrosis factor (TNF) family and are important regulators of
B-cell maturation, survival, and function [3,4].
They regulate the size and composition of B-cell compart-
ment and act as important driving factors for B-cell hyperpla-
sia and autoantibody production in autoimmune processes [5].
BLyS and its homolog APRIL are widely expressed by
many cell types, including hematopoietic and stromal cells
[6]. There are two forms of BLyS, membrane-bound and solu-
ble. The gene expression and the levels of BLyS are regulated
by cytokines, basically interferon-c and to a lesser extent inter-
leukin-10 [7].
The binding of BLyS and APRIL to their receptors acti-
vates speciﬁc TNF receptor-associated factors (TRAFs), which
regulate signal transduction in B cells [8,9].
Beside their well-known function as antibody secreting
cells, an antibody independent role for B-cells in disease
pathogenesis has been documented by experimental data as
well as the promising results of B-cell depleting therapies in
RA [10–12].
Juvenile idiopathic arthritis (JIA) is a heterogeneous condi-
tion gathering distinct forms of chronic arthritides of unknown
etiology that begin before the age of sixteen and persist for at
least six weeks [13].
SLE is a systemic autoimmune disease characterized by
autoantibody production against self-antigens [14]. The role
of BAFF (BLyS) in the pathogenesis and disease activity in
SLE is well-known and the novel noticeable correlation with
the damage index highlights the utility of BAFF as an indica-
tor of disease damage and predictor of poor outcome [15]. The
rationale for developing B-lymphocyte (BLyS) inhibitors has
included successive investigations. B-cell stimulatory factors
that can promote the loss of B-cell tolerance and drive autoan-
tibody production are exciting new candidates [14].This study was designed to assess the relationship of serum
BLyS/APRIL levels to disease activity in pediatric pSLE and
JIA patients.2. Patients and methods
2.1. Study approval
This study was approved by the Ethics Committee of our insti-
tution (Benha faculty of medicine). Legal guardians of all sub-
jects gave their written informed consent before participation
in this study.2.2. Participants
This study included 82 children recruited from the inpatient
and outpatient clinics of the rheumatology and pediatric
departments, faculty of medicine, Benha University Hospitals.
Twenty-nine pediatric patients met the American College of
Rheumatology (ACR) criteria for SLE classiﬁcation [16], while
33 juvenile patients were diagnosed as juvenile idiopathic
arthritis (JIA) according to the International League Against
Rheumatism (ILAR) classiﬁcation criteria [17]. Twenty age
and gender matched children served as controls.
The following information was obtained: demographic data
(age, gender, age at disease onset, duration of disease), JIA
subtype, number of active joints, clinical manifestations of
pediatric SLE (pSLE) patients at presentation, laboratory val-
ues and treatment data (biologics, concomitant DMARDs and
corticosteroids including start and stop dates, as well as rea-
sons for withdrawal).
pSLE patients were evaluated using the systemic lupus
erythematosus disease activity index (SLEDAI) [18] while,
nephritis was classiﬁed according to the World Health Organi-
zation (WHO) classiﬁcation based on patients’ previous data
[19]. JIA patients were evaluated using the juvenile arthritis
27 joints disease activity score (JADAS-27) [20].2.3. Laboratory investigations
Complete blood cell count (CBC), erythrocyte sedimentation
rate (ESR) by the Westergren method, complete urine analysis
for casts and/or proteinuria, IgM rheumatoid factor (RF)
done by Rose–Waaler test, antinuclear antibody (ANA) and
double-stranded DNA antibodies (anti-dsDNA) done by indi-
rect immunoﬂuorescence on Hep-2 cells by Kallestad HEp-2
Slides and Kallestad indirect ﬂuorescent antibody (IFA) assays
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kits were supplied from Biorad.
2.4. Serum BLyS and APRIL determination
Assay of BLyS and APRIL was made by the enzyme linked
immunosorbent assay (ELISA) technique using the kit sup-
plied from R&D Systems, Inc (USA). Human BAFF/BLyS/
TNFSF13B (Catalog Number DBLYS0) Immunoassay was
used for BAFF assay. Intra-Assay Precision (CV) was 3.8%.
Inter-Assay Precision (CV) was 7.8% for Human BAFF/
BLyS/TNFSF13B Immunoassay. Human APRIL/TNFSF13
Catalog Number: DY884 was used for assay of serum APRIL.
Both assay procedures were followed according to the manu-
facturer’s instructions.
Statistical analysis: The collected data were analyzed using
SPSS version 16. Categorical data were presented as number
and percentages while continuous variables were presented as
mean and SD if parametric, and median and range if non para-
metric. Chi square, Z test, Mann Whitney U test, Kruskal–
Wallis test and Spearman’s correlation coefﬁcient were used
as tests of signiﬁcance. Two sided p-value <0.05 was consid-
ered signiﬁcant.3. Results
3.1. Demographic and clinical characteristics of the study groups
The present study comprised 29 pSLE patients (females to
males, 25:4 with median age 14.3 years) and 33 JIA patients (fe-
males to males, 23:10 with median age 12.2 years). JIA patients
were further classiﬁed into 6 systemic-onset, 12 polyarticular
and 15 oligoarticular subtypes. Nephritis was observed in 8
pSLE patients (27.58%), one patient was class II nephritis,
2 patients class were III, one was class IV and 3 were class V,
while the nephritis class could not be determined in one patient.
The median SLEDAI was 12 (range 6–28), while the median
JADAS-27 of JIA patients was 15.1 (5–37) with no signiﬁcant
differences noted among different subtypes (p= 0.16).
Although the pSLE patients had shorter disease duration
than JIA patients, no signiﬁcant difference was noted between
them (p< 0.05). Marked signiﬁcant differences between
pSLE and JIA patients were observed regarding certain medi-
cations, with more pSLE patients receiving corticosteroids
(p< 0.001), azathioprine (p< 0.001) and cyclophosphamide
(p= 0.013), while more JIA patients received methotrexate
(p< 0.001). There were no differences regarding (NSAIDs)
(p= 0.57) and hydroxychloroquine (p= 0.86) therapy. Only
one polyarticular JIA patient was receiving etanercept (anti-tu-
mor necrosis factor treatment). Characteristics of the studied
patients are shown in Table 1.
3.2. BLyS and APRIL levels in pSLE
The median BLyS serum level was 1.14 ng/ml in pSLE patients
(range 0.2–2.13) and 0.58 ng/ml in healthy controls (range 0.04–
1.06), p< 0.001. Sera from patients with pSLE also showed a
high median APRIL serum level of 11 ng/ml (range 0.11–205)
compared to healthy controls (0.9 ng/ml, range 0.0–23.4),
p= 0.046.Higher serum levels of both BLyS and APRIL were associ-
ated with lower incidence of renal involvement (p= 0.043 and
p= 0.016, respectively). Meanwhile, higher serum APRIL lev-
els associated absence of anti-dsDNA (p= 0.017), while serum
BLyS did not (p= 0.197), (Table 2).
Only serum BLyS was signiﬁcantly higher in patients
receiving cytotoxic drugs (azathioprine, cyclophosphamide)
(p= 0.017). On the other hand, neither high prednisone doses
(>1 mg/kg/day) nor gender signiﬁcantly affect serum BLyS
(p= 0.83, p= 0.23, respectively) or APRIL (p= 0.56,
p= 0.25, respectively) levels, Table 2.
Serum BLyS levels correlated positively with disease activ-
ity (r= 0.38, p= 0.042). Inverse correlations between serum
APRIL levels and disease activity (r = 0.429, p= 0.02) in
pSLE patients were observed, Fig. 1(A and B). There were
no signiﬁcant correlations between serum BLyS, or APRIL
levels with age, disease duration or blood leukocyte and lym-
phocyte counts (p< 0.05).
3.3. BLyS and APRIL levels in JIA disease
Serum BLyS levels were signiﬁcantly higher in JIA patients
(median 1.18 ng/ml, range 0.2–4.21) compared to controls
(median 0.58 ng/ml, range 0.04–1.06), p< 0.001. The median
serum BLyS level was signiﬁcantly elevated in systemic onset,
3.52 ng/ml (range 1.23–4.21) compared to polyarticular onset,
1.25 ng/ml (range 0.45–4.12) and oligoarticular onset, 1.04 ng/
ml (range 0.2–2.59) with p= 0.007. The median APRIL Level
was 35.3 ng/ml (range 0.8–211) in sera of patients with JIA and
0.9 ng/ml (range 0.0–23.4) in sera of healthy controls
(p< 0.001). A signiﬁcantly elevated median APRIL level
(p= 0.004) was found in sera of systemic onset patients
(184.5 ng/ml, range 33.6–211) compared to polyarticular onset
(41.75 ng/ml, range 3.5–201) and oligoarticular onset (23 ng/
ml, range 0.8–100).
Both BLyS and APRIL levels were signiﬁcantly elevated in
sera of JIA patients with positive ANAs (p= 0.008,
p< 0.001, respectively). Only serum BLyS was signiﬁcantly
higher in JIA patients with uveitis (p= 0.031) and APRIL
was higher in sera of those with a positive RF (p= 0.035).
There was a signiﬁcant increase of serum BLyS levels in pa-
tients receiving DMARDs compared to other patients
(p= 0.006). Also, there were no signiﬁcant differences in ser-
um levels of APRIL between JIA patients receiving and not
DMARDs (p< 0.05). BLyS and APRIL levels among sera
of JIA patients did not differ signiﬁcantly with respect to
gender or corticosteroid doses (prednisone P1 mg/kg/d),
(p< 0.05), (Table 3).
Both BLyS and APRIL levels signiﬁcantly correlated with
disease activity (r= 0.497, p= 0.019 and r= 0.549,
p= 0.001, respectively) in sera of JIA patients, Fig. 1 (C and
D). Neither BLyS nor APRIL correlated with age, disease
duration or thrombocyte count (p< 0.05). APRIL and BLyS
serum levels correlated positively to each other in JIA patients
but inversely in pSLE patients (r= 0.469, p= 0.006 and
r= 0.403, p= 0.03, respectively), Fig. 1 (E and F).4. Discussion
Autoreactive B cells are driven by self-antigens, but the fac-
tors that promote the loss of B cell tolerance and drive
Table 1 Demographic and disease characteristics of pSLE and JIA patients.
Controls
(n= 20)
pSLE patients
(n= 29)
JIA patients
All JIA
(n= 33)
Systemic
(n= 6)
Polyarticular
(n= 12)
Oligoarticular
(n= 15)
Median age (range)/years 12.5(3–15) 14.3 (9.6–16.8) 12.2 (3–16) 10 (3–15) 14.3 (7–16) 11 (4–16)
Female/male (No.) 14/6 25/4 23/10 4/2 7/5 12/3
Disease duration(years)
Median (range) – 4.6 (0.0–7.3) 5.4 (1–11) 5 (1–10) 6(2–11) 5(2–11)
SLEDAI median (range) NA 12 (6–28) – – – –
JADAS-27 median (range) NA – 15.1 (5–37) 16.7(5–25.2) 16.1(9–37) 12.5(5.9–17)
Laboratory ﬁndings
–WBCs · 103/mm3 median (range) NA 4.9 (2.5–14.7) 7.2(3.9–14.2) 6.7(4.5–14.2) 7.3(3.9–12.9) 6.9(4.2–13.2)
–Lymphocytes · 103/mm3 median (range) NA o.38 (0.05–0.77) 0.41(0.12–0.7) 0.40(0.15–0.7) 0.41(0.11–0.8) 0.43(0.12–0.7)
–Thrombocytes103/mm3 median (range) NA 170.6(70.5–250) 447(180.6–544.8) 470.5(243–544.8) 346.8(215–490) 319.8(180.6–422)
–ANA, +ve no (%) – 29 (100) 15(39.58) 1(9.09) 5(31.25) 13(61.9)
–Anti-dsDNA, +ve no (%) – 26(89.65) 0(0) 0(0) 0(0) 0(0)
–RF, +ve no (%) – 3(10.34%) 5(10.4) 0(0) 4(25) 1(4.8)
Medications, no (%)
–NSAIDs 12(41.37) 16(48.48) 3 (50) 9(75) 4 (26.66)
–Predisolone < 1 mg/kg/d 25(86.2) 8(24.24) 5(83.33) 2(16.66) 1 (6.66)
–PredisoloneP 1 mg/kg/d 3(10.34) 3(9.09) 3(50) 0(0) 0 (0)
–Hydroxychloroquine 26(89.65) 11(33.33) 0(0) 7(58.33) 4 (26.66)
–Methotrexate 1(3.44) 23(69.69) 3(50) 12(100) 8 (53.33)
–Etanercept 0 (0) 0(0) 0 (0) 1(8.33) 0 (0)
–Azathioprine 15(51.72) 0 (0) 0 (0) 0 (0) 0 (0)
–Cyclophosphamide 5(17.24) 0 (0) 0 (0) 0 (0) 0 (0)
pSLE, pediatric systemic lupus erythematosus; JIA, juvenile idiopathic arthritis; SLEDAI, systemic lupus erythematosus disease activity index;
JADAS-27, juvenile arthritis 27 joint disease activity score; WBC, white blood cell; ANA, antinuclear antibody; Anti-dsDNA, anti-double
stranded DNA; RF, rheumatoid factor; NSAIDs, non-steroidal anti-inﬂammatory drugs; NA, not applicable.
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considered as a fundamental survival factor for transitional
and mature B cells, whereas APRIL mainly affects B1 cell
activity, humoral responses and class switching of immuno-
globulins [3].
Whereas many previous studies have evaluated the role
of BLyS in adult populations with various immune based
diseases [22–29], debated yet little information is available
about serum APRIL levels in adult patients with SLE [29–
31] and almost none on pSLE. Important differences do ex-
ist between pSLE and adult SLE and between JIA and adult
RA [2]. Few studies have involved association of BLyS/
APRIL in pediatric patients with autoimmune diseases
[2,32], whereas one study assessed plasma BLyS protein
and blood leukocyte BLyS mRNA in pSLE and JIA pa-
tients [2], another study [32] assessed BLyS/APRIL serum
levels in JIA patients only.
One of the hallmarks of active disease in human SLE is the
increased percentages of activated B cells and plasma cells in
peripheral blood [33,34]. Concurring with previous studies,
we demonstrated increased serum BLyS levels in pSLE pa-
tients compared to healthy controls with a signiﬁcant correla-
tion to disease activity (p= 0.042) [2].
In addition, similar previous ﬁndings in a study done on
adult SLE patients reported a signiﬁcant correlation between
changes in circulating BLyS levels and changes in disease
activity [26]. A better correlation of disease activity with blood
leukocyte BLyS mRNA levels than with plasma BLyS protein
levels was documented in another cross-sectional observa-tional study [25]. Meanwhile, other studies did not ﬁnd any
association between BLyS serum levels and SLE activity in
adult patients [22,23]. These disparities are not surprising as
clinical manifestations of SLE are diverse and differences in
the pathogenesis between adult and pSLE may be present.
Elevated APRIL levels were also observed in our pSLE pa-
tients compared to healthy controls with a limited inverse cor-
relation to disease activity (p= 0.02). Similar results were
obtained in previous studies in adult SLE patients [29–31],
whereas a signiﬁcant correlation between serum APRIL levels
and musculoskeletal manifestations among patients with adult
SLE when assessed by the BILAG index was reported in an-
other study [30].
On comparing serum BLyS and APRIL levels with differ-
ent clinical parameters, serological markers and management
protocols, there was no association between serum BLyS levels
and anti-dsDNA antibody while contradictory results were ob-
tained with serum APRIL levels, whereas lower serum APRIL
levels were found when anti-dsDNA antibody was present.
The direct link between anti-DNA antibodies and nephritis
has been demonstrated [35,36], as well as its titers have been
considered as a predictor of renal ﬂare [37]. Moreover, Reich-
lin et al. [38] stated that both anti-dsDNA and anti-ribosomal
P antibodies were associated with a higher prevalence of renal
involvement in juvenile SLE.
Since these antibodies are strongly associated with nephritis
in SLE this may explain the lower incidence of renal
involvement in our patients with high serum BLyS and APRIL
levels.
Figure 1 (A and B) Correlation between B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) serum levels, and
systemic lupus erythematosus disease activity index (SLEDAI); (C and D) correlation between BLyS and APRIL serum levels, and
juvenile arthritis disease activity score (JADAS-27); (E and F) correlation between BLyS and APRIL serum levels in pediatric systemic
lupus erythematosus (pSLE) and juvenile idiopathic arthritis (JIA) patients, respectively.
Table 2 Comparison between BLyS and APRIL serum levels in different parameters of pSLE patients.
BLyS (ng/ml) median (range) p APRIL(ng/ml) median (range) p
Gender Females (25) Males (4) 1.13 (0.2–2.13) 1.24 (1.1–2.01) 0.23 10 (0.11–155) 56 (0.5–205) 0.25
Lupus nephritis +ve (8) –ve (21) 1.12 (0.2–1.85) 1.24 (0.7–2.13) 0.043* 5 (0.11–70) 56.5 (0.5–205) 0.016*
Anti-DNA +ve (26) –ve (3) 1.14 (0.2–2.13) 1.39 (1.02–2.11) 0.197 7.5 (0.11–205) 144 (53–155) 0.017*
Cytotoxic agents Yes (21) No (8) 1.21 (0.8–2.13) 0.8 (0.2–1.25). 0.017* 11 (0.11–205) 15 (0.5–100) 0.96
Predisolone P1 mg/kg/d Yes (3) No (26) 1.12 (0.82–2.13) 1.17 (0.2–2.11) 0.83 0.8 (0.8–40) 11.5 (0.11–205) 0.56
Anti-DNA, anti-double stranded DNA; BLyS, B lymphocyte stimulator; APRIL, a proliferation-inducing ligand.
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BLyS in adult SLE patients, especially among those with clin-
ically overt renal involvement. On the other hand, circulating
soluble APRIL may not be the only form of APRIL relevant
to B cell biology and/or B cell based autoimmunity [31].
In concordance with our results, Morel et al. [29], found an
inverse correlation between serum APRIL and anti-dsDNA
antibody titers, they did not report any correlation betweenserum BLyS and anti-dsDNA antibody titers. In other studies,
serum BLyS correlated with anti-dsDNA antibody titers in
adult SLE patients [22,40].
Interestingly, serum BLyS levels were higher in pSLE pa-
tients receiving cytotoxic drugs. This contradiction could be
attributed to the fact that patients with more active disease re-
ceive more cytotoxic drugs. Adult RA or SLE patients treated
with rituximab demonstrated reductions in B cell loads among
Table 3 Comparison between BLyS and APRIL serum levels in different clinical, laboratory and therapeutic variables of JIA
patients.
BLyS (ng/ml) median (range) p APRIL (ng/ml) median (range) p
Gender Females (23) Males (10) 1.31 (0.2–4.21) 1.11 (0.21–4.11) 0.32 27.5 (0.8–211) 19.5 (0.8–40) 0.27
Uveitis +ve (13) ve (20) 2.13 (0.2–4.21) 1.09 (0.21–2.59) 0.031* 152 (0.8–211) 24(0.8–142) 0.051
ANA +ve (15) ve(18) 2.03 (0.2–4.21) 1.03 (0.21–4.11) 0.008* 142 (13.11–211) 21.5 (0.8–40) <0.001*
RF +ve (5) ve (28) 1.32 (0.89–3.9) 1.18 (0.2–4.21) 0.48 100 (36–211) 29.3(0.8–211) 0.035*
Cytotoxic agents Yes (23) No (10) 1.32 (0.2–4.21) 0.84 (0.21–1.85) 0.006* 47.5(0.8–211) 24.25(0.8–40) 0.07
Prednisolone P1 mg/kg/d Yes (3) No (30) 1.32 (1.21–2.13) 1.18 (0.2–4.21) 0.57 36(13.11–211) 34.46(0.8–211) 0.66
ANA, antinuclear antibody; RF, rheumatoid factor; BLyS, B lymphocyte stimulator; APRIL, a proliferation-inducing ligand.
98 G.G. Elolemy et al.those under therapy that may have resulted in the elevated cir-
culating BLyS protein levels [41]. The data presented here
demonstrate that corticosteroid therapy has no signiﬁcant role
in BLyS/APRIL serum levels in pSLE patients concurring with
previous results [2].
In our JIA patients, elevated serum levels of both BLyS and
APRIL were observed and signiﬁcantly correlated with disease
activity (p= 0.019, p= 0.001, respectively). Gheita et al. [32]
found increased BAFF (BLyS) and APRIL serum levels in JIA
patients associated with disease activity.
In contrast, no correlation has been reported between plas-
ma BLyS protein concentration and disease activity, however,
the Childhood Health Assessment Questionnaire (CHAQ)
which is a measure of functional disability, was used to evalu-
ate disease activity [2].
B-cell pathology plays an important role in early-onset JIA.
B-cells function as ampliﬁers of chronic inﬂammation in the
disease progress of JIA and might be a target of future thera-
pies [42]. A profound decrease in circulating natural killer
(NK) cells with coexisting hypergammaglobulinemia in JIA
consistent with B-cell hyperactivity has been reported [43].
Thus, BLyS might play a crucial role in early activation of
self-antigen-driven autoimmune B cells with autoimmune T
cells further driving the switch for the production of patho-
genic IgG autoantibodies [22].
In agreement with a previous report [32], we demonstrated
elevated serum levels of BLyS and APRIL in systemic onset
JIA patients compared to other types of onset. Furthermore,
BLyS levels were signiﬁcantly higher in JIA patients with uve-
itis. A primarily B-cell-inﬁltrative process of an enucleated eye
globe has been observed in a 12-year-old patient with recurrent
oligoarticular JIA [44].
Presence of RF was associated with higher APRIL levels in
JIA. There was no comment in the results on BLYS or APRIL
levels in RF positive or negative pSLE patients.
A signiﬁcant correlation between BLyS and APRIL in ser-
um of JIA patients was found in our study, in agreement with
a previous report [32]. Similar to our results, Morel et al. [29]
established an inverse correlation between BLyS and APRIL
in serum of adult SLE patients, suggesting a protective role
of APRIL.
In conclusion, serumBLyS showed elevated levels that corre-
lated signiﬁcantly with pSLE and JIA disease activity, accord-
ingly anti-BLyS therapy might be of great beneﬁt to offset
disease ﬂare. The inverse correlations observed between APRIL
with both BLyS levels and disease activity in pSLE patients raise
the possibility of being a down regulator of the disease process.Conﬂict of interest
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